ICON plc
, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the expansion of its US and UK bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.
ICON has increased its bioanalytical laboratories in Whitesboro, New York, and Manchester, UK, by 7,000 and 4,000 square feet respectively. The expansions allow ICON to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays. Operating since 1988, ICON’s Whitesboro facility already features multiple wet laboratories and instrument laboratories for small and large molecules, including a specially designed hazardous lab for the analysis of HIV & Hepatitis B infected samples. Similarly, ICON’s Manchester laboratory has provided bioanalytical support for both small and large molecule studies for almost 30 years and is located close to ICON's hospital-based Clinical Pharmacology Unit in Manchester.
“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” commented Brian O’Dwyer, Senior Vice President of Global Bioanalytical Services, ICON Development Solutions. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.